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Abstract
Purpose When during cancer treatment resistance to a tyrosine
kinase inhibitor (TKI) occurs, switching to another TKI is often
considered as a reasonable option. Previously, we reported that
resistance to sunitinib may be caused by increased lysosomal
sequestration, leading to increased intracellular lysosomal stor-
age and, thereby, inactivity. Here, we studied the effect of sev-
eral other TKIs on the development of (cross-) resistance.
Methods TKI resistance was induced by continuous exposure
of cancer cell lines to increasing TKI concentrations for 3–
4 months. (Cross-) resistance was evaluated using MTT cell
proliferation assays. Intracellular TKI concentrations were
measured using LC-MS/MS. Western blotting was used to
detect lysosome-associated membrane protein-1 and −2
(LAMP1/2) expression.
Results The previously generated sunitinib-resistant (SUN)
renal cancer cells (786-O) and colorectal cancer cells (HT-
29) were found to be cross-resistant to pazopanib, erlotinib
and lapatinib, but not sorafenib. Exposure of 786-O and HT-
29 cells to sorafenib, pazopanib or erlotinib for 3–4 months
induced drug resistance to pazopanib and erlotinib, but not
sorafenib. Intracellular drug accumulation was found to be
increased in pazopanib- and erlotinib-, but not in sorafenib-
exposed cells. Lysosomal capacity, reflected by LAMP1/2
expression, was found to be increased in resistant cells and,
in addition, to be transient. No cross-resistance to the mTOR
inhibitor everolimus was detected.
Conclusions Our data indicate that tumor cells can develop
(cross-) resistance to TKIs, and that such resistance includes
increased intracellular drug accumulation accompanied by in-
creased lysosomal storage. Transient (cross-) resistance was
found to occur for several of the TKIs tested, but not for
everolimus, indicating that switching from a TKI to a mTOR
inhibitor may be an attractive therapeutic option.
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1 Introduction
The human kinome encodes 518 protein kinases, many of
which are deregulated in cancer [1]. Receptor tyrosine ki-
nases, belonging to the vascular endothelial growth factor
(VEGF) signaling pathway, serve as validated clinical antican-
cer targets for tyrosine kinase inhibitors (TKIs) such as suni-
tinib, sorafenib and pazopanib [2]. These multi-targeted TKIs
have shown clinical benefit as monotherapy in renal cell can-
cer, and their application is currently expanding to other tumor
types [3]. Despite their clinical benefit, however, complete
remissions are rare and with time patients invariably suffer
from disease progression, leading to discontinuation of treat-
ment. In case of progression or unacceptable toxicity for either
one of these TKIs, switching to another TKI is considered as a
bona fide treatment option [4, 5]. Such sequential use can
indeed be effective, i.e., pazopanib and sorafenib have shown
clinical activity after sunitinib failure, suggesting that cross-
resistance may be only partial [5, 6].
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Currently, detailed information is lacking on patterns of
resistance or cross-resistance of tumor cells to long-term ex-
posure to multi-targeted TKIs. Contrary, single targeted TKIs,
such as e.g., vemurafenib, targeting the BRAFV600E mutation
in melanomas, or gefitinib, targeting activating EGFR muta-
tions in lung cancer, often lead to the development of second-
ary drug-resistant kinase mutations thereby, at least partly,
explaining the development of TKI resistance [7]. As yet, it
is poorly understood how tumor cells respond to long-term
kinase inhibitor exposure, e.g., to the clinical administration
of sunitinib, where partial responses are most commonly ob-
served. We have recently mimicked prolonged sunitinib expo-
sure in vitro and showed that continuous exposure to sunitinib
for several months can induce resistance to this TKI in 786-O
renal cell cancer and the HT-29 colorectal cancer cell lines [8].
Importantly, when grown as in vivo xenografts in mice, the
HT-29 sunitinib-resistant cell line remained resistant (unpub-
lished result). In addition, we found that sunitinib resistance
was accompanied by an increased lysosomal storage capacity
and was reversible upon removal of the drug within several
weeks. Therefore, this transient form of resistance may be an
adaptation to (partial) inhibition ofmultiple kinases and/or to a
partly disturbed lysosomal function, rather than a stable, ge-
netic form of resistance. These results support other prelimi-
nary reports indicating that re-challenging of patients with
sunitinib, after a certain recovery period, may be a bona fide
treatment option [9, 10].
In order to obtain further insight into the possible conse-
quences of long-term administration of sunitinib or other TKIs
to the sensitivity of tumor cells to second line therapy, we
explored the resistance and cross-resistance patterns of tumor
cells to several multi-targeted TKIs and the mTOR inhibitor
everolimus. Since there is preclinical and clinical evidence for
the existence of synergistic interactions between EGFR and
VEGFR inhibitors in various tumor types [11–13], we also
included erlotinib and lapatinib in our current study. We found
that sunitinib-resistant tumor cells are cross-resistant to some,
but not all, TKIs tested in conjunction with increased intracel-
lular drug accumulation. Upon continuous exposure of both
786-O and HT-29 cells, resistance could be induced to some
TKIs, and the results are comparable to the cross-resistance
findings. Furthermore, in the resistant cells the lysosomal
compartment was increased as revealed by increased
LAMP1/2 expression.
2 Materials and methods
2.1 Reagents
Sunitinib malate was kindly provided by Pfizer Oncology
(New York, NY). Sorafenib, pazopanib, erlotinib hydrochlo-
ride, lapatinib di-p-toluenesulfonate and everolimus were
purchased from LC Laboratories (Woburn, MA). All drugs
were prepared as 20 mM stock solutions in DMSO (Sigma-
Aldrich), except erlotinib hydrochloride, which was prepared
as a 10 mM stock solution in 96% DMSO/4% H2O. All stock
solutions were stored at −80 °C.
2.2 Cell culture
786-O renal cell cancer (RCC) and HT-29 colorectal cancer
(CRC) cell lines were cultured in DMEM supplemented with
5% fetal bovine serum (FBS) and maintained in a humidified
incubator containing 5% CO2 at 37 °C. Both cell lines were
purchased from the American Tissue Culture Collection
(ATCC) and were authenticated by STR profiling (Baseclear,
Leiden, Netherlands). The generation of the sunitinib-resistant
sub-lines 786-O SUN and HT-29 SUN, continuously cultured
in the presence of 5 μM or 10 μM sunitinib, respectively, has
been described previously [8]. To induce resistance to sorafe-
nib, pazopanib and erlotinib, the parental cell lines 786-O and
HT-29 were continuously exposed for 3–4 months to gradu-
ally increasing concentrations of the respective drugs. The
initial exposure concentrations were set between the IC10
and IC50 values for each specific compound. When cells
reached confluence, they were split and the TKI concentration
was at maximum doubled in the subsequent culture period.
This procedure was repeated for 3–4 months, until a stable
well-tolerated TKI concentration was reached and TKI sensi-
tivity was tested as described below.
2.3 MTT proliferation assay
The (cross-) resistance to different drugs was evaluated by
MTT proliferation assays as previously described [8]. Briefly,
all cells were seeded in 96-well culture plates without drug
and allowed to adhere for 24 h. Subsequently, t=0 was mea-
sured using MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diophenyl
tetrazolium bromide) and drugs were added at different con-
centrations (in 3-fold). After 96 h, proliferation was assessed
using MTT. Experiments were repeated 3 times independent-
ly, unless stated otherwise.
2.4 TKI measurements by LC-MS/MS
Parental and sunitinib, sorafenib, pazopanib or erlotinib ex-
posed cells were seeded in 6-well culture plates and allowed to
adhere for 48 h. Next, cells were washed once with PBS and
incubated with TKI-containing medium as indicated. After
24 h, cells were washed three times with ice-cold PBS after
which cells were trypsinized at 37 °C for 5 min and, when
detached, ice-cold PBS was added. Next, samples were re-
suspended, collected and counted. After centrifugation at 13,
000 rpm/ 4 °C for 10 min, the supernatant was discarded and
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pellets were snap frozen in liquid nitrogen and stored at
−80 °C until analysis.
For TKI accumulation analyses, cell pellets were
reconstituted in 100 μl of Milli-Q water and homogenized
by gentle aspiration. Subsequently, 20 μl of the homogeneous
solution was mixed with 80 μl of ice cold acetonitrile in a
round bottomed 96-well plate; a plate seal was applied to
prevent evaporation. After careful ultra-sonication for 30 s,
the plate was centrifuged at 4 °C/1,000×g for 10 min and
50μl solutionwas transferred to a conical 200μl 96-well plate
for injection on the optimized liquid chromatography - tandem
mass spectrometry system (LC-MS/MS system). Chromato-
graphic parameters and mass spectroscopic parameters for su-
nitinib, sorafenib and erlotinib were as previously reported
[14]. Optimized pazopanib parameters were determined using
a standard reference compound diluted to 1 μg/ml in mobile
phase and linearity, accuracy and precision parameters were
determined for responses across a concentration range of 5–
5000 ng/ml.
2.5 Western blot analysis
Parental and sorafenib, pazopanib or erlotinib exposed cells
were seeded in TKI-containing medium and allowed to grow
for 48 h. Before lysis, cells were washed twice with ice-cold
PBS. Cell lysates were prepared using M-PER mammalian
protein extraction reagent (Thermo Scientific) supplemented
with protease and phosphatase inhibitor cocktails (Thermo
Scientific). Cells were incubated with the lysis buffer mixture
for 20 min on ice, scraped off, collected and, subsequently,
centrifuged at 10,000×g for 15 min at 4 °C. The supernatant
was collected and stored at −80 °C until analysis. Cell lysates
were prepared three times independently. Protein concentra-
tions were determined using a micro BCA protein kit (Thermo
Scientific). Samples containing 20–50 μg protein were sub-
jected to 10 % SDS polyacrylamide gel electrophoresis and,
subsequently, transferred to PVDF membranes (Immobilon-
FL, Millipore). Proteins were detected using the following
antibodies (catalogue numbers in parentheses): anti-LAMP-1
(sc-20011), anti-LAMP-2 (sc-18822) (Santa Cruz biotechnol-
ogy) and anti-β-actin (A5441) (Sigma-Aldrich). After incuba-
tion with IRDye infrared dye labeled secondary antibodies
(LI-COR Biosciences), membranes were scanned using an
Odyssey Infrared Imaging System (LI-COR Biosciences).
Protein expression was determined using the accompanying
software program (LI-COR Biosciences) and corrected for β-
actin expression. Expression levels were normalized to un-
treated samples.
2.6 Statistical analyses
Data are expressed as mean±standard error of the mean
(SEM). When appropriate, results are shown as normalized
data. Statistical analyses were performed using Student’s t-
test. Resistance is defined as resistance factor >2.5, calculated
as IC50 value of the exposed cell line divided by the IC50 value
of the parental cell line. A p value<0.05 was considered to be
statistically significant.
3 Results
3.1 TKI sensitivity of parental 786-O and HT-29 cells
First, we determined the sensitivity of the parental cell lines
786-O PAR and HT-29 PAR to the tyrosine kinase inhibitors
(TKIs) sunitinib, sorafenib and pazopanib, to the EGFR TKIs
erlotinib and lapatinib and to the mTOR inhibitor everolimus
in 96 h proliferation assays. The sensitivities to the respective
TKIs were found to be in the same, low micro-molar range
(Fig. 1a), with IC50 values between 0.8 and 6.5 μM (Table 1),
and were comparable between the two cell lines. The mTOR
inhibitor everolimus showed a different sensitivity curve com-
pared to the TKIs and reached a plateau between ~1 nM and
10 μM, at which the proliferation hardly decreased (~IC60
(786-O) and~IC30 (HT29); Fig. 1b).
3.2 TKI cross-resistance in sunitinib-resistant 786-O
and HT-29 cells
First, we confirmed our previously reported [7] sunitinib-
resistance in the 786-O SUN and HT-29 SUN cell lines with
a resistance factor (RF) of 3–4 fold (Fig. 2a and Table 1).
Subsequently, we determined the sensitivity of 786-O SUN
and HT-29 SUN cells to sorafenib, pazopanib, erlotinib,
lapatinib and everolimus (Fig. 2a and Table 1). Erlotinib
showed a pronounced cross-resistance in both 786-O SUN
and HT-29 SUN cells (RF≥4.5 and>3.2, respectively) and
did not reach an IC50 within the tested concentration range.
Pazopanib showed cross-resistance in HT-29 SUN cells (RF=
22), but not in 786-O SUN cells (RF=1.6). Two other TKIs,
sorafenib and lapatinib, showed no cross-resistance in the
sunitinib-resistant cells. The effect of everolimus on cell pro-
liferation was modest over a wide concentration range in the
parental cells, with no detectable cross-resistance in the
sunitinib-resistant cell lines.
Since we previously showed [8] that sunitinib-resistance
may be associated with an increased intracellular accumula-
tion of the drug, we also measured intracellular sorafenib,
pazopanib and erlotinib concentrations in the SUN compared
to the PAR cell lines (Fig. 2b). First, we confirmed that the
total intracellular accumulation of sunitinib was increased in
the resistant cells. Next, we found that the accumulation of
erlotinib was also increased (2–8 fold higher in the sunitinib-
resistant cell lines). Pazopanib showed a 2-fold higher
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accumulation in HT-29 SUN cells compared to HT-29 PAR
cells, but a similar accumulation in 786-O SUN and PAR
cells. Compared to their respective parental cells, sorafenib
showed a 3-fold higher accumulation in HT-29 SUN cells,
but a lower accumulation in 786-O SUN cells.
3.3 Induction of multiple TKI cross-resistances in 786-O
and HT-29 cells
In order to investigate whether the resistant phenotype induced
by sunitinib may represent an universal resistance mechanism,
we exposed 786-O PAR and HT-29 PAR cells continuously for
3–4 months to increasing concentrations of the multi-targeted
TKIs sorafenib and pazopanib and to the single-targeted TKI
erlotinib to compare resistance induction to an EGFR family
TKI. The induction of resistance by these three TKIs was found
to be comparable to their cross-resistance phenotype in the
sunitinib-selected cells: a prominent resistance to pazopanib
and erlotinib (RF≥3.1 ->25) and no development of resistance
to sorafenib (RF=1.2; Fig. 3a and Table 2). The final
concentration after 3–4 months of exposure was 3 μM sorafenib
and 20 μM pazopanib or erlotinib, respectively. Higher concen-
trations of pazopanib and erlotinib could not be achieved due to
their limited solubility in culture medium. Pazopanib- or
erlotinib-resistant cells, as well as sorafenib-exposed cells, did
not show cross-resistance to any of the other drugs tested (i.e.,
sunitinib, sorafenib, pazopanib, erlotinib, lapatinib, everolimus;
data not shown). The intracellular accumulation of the selected
TKIs (sorafenib, pazopanib, erlotinib) was measured in these
continuously exposed cells and compared to shortly exposed
parental cells. By doing so, a~5–50 fold increase in
pazopanib and erlotinib content, but not in sorafenib con-
tent, was found in the continuously exposed cells com-
pared to the parental cells (Fig. 3b).
As a measure for the lysosomal compartment the lysosome-
associated membrane proteins LAMP-1 and LAMP-2, which
are the most abundant constituents of the lysosomal membrane
[15], were measured by Western blotting. These proteins were
previously found to be increased in the sunitinib-resistant cells
and to be reverted to control levels when cells became sensitive
a
b
Fig. 1 Sensitivity of (parental)
786-O and HT-29 tumor cells to
different inhibitors. Proliferation
assays (MTT) of 786-O (left) and
HT-29 (right) parental cell lines
incubated with different concen-
trations of (a) the tyrosine kinase
inhibitors (TKIs) sunitinib, soraf-
enib, pazopanib, erlotinib or
lapatinib or (b) the mTOR inhib-
itor everolimus. Results are
shown as mean ± SEM
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again [8]. Through Western blot analysis, we found that both
LAMP-1 and LAMP-2 were expressed at increased levels
in most of the continuously exposed cell lines tested
(Fig. 3c). Quantification revealed a 1.5 - 2 fold increase
in LAMP-1 and LAMP-2 expression levels for the three
TKIs in the continuously exposed 786-O and HT-29 cell
lines, except for the 786-O SOR cell line in which LAMP-
1 expression was found to be unaltered (Fig. 3d).
3.4 Pazopanib resistance induction and reversal in 786-O
and HT-29 cells
The remarkable pazopanib-resistance, which was ob-
served after 3–4 months continuous exposure to this
drug, is of particular interest because of its increasing
clinical use [2]. Therefore, additional experiments aimed
at establishing a time-course for resistance induction and
its subsequent reversibility were performed. To this end,
786-O and HT-29 cells were exposed to pazopanib for 1,
2 and 4 weeks. We found that resistance to pazopanib
developed rapidly in 786-O cells and was fully present
after a 2 week exposure, whereas such resistance devel-
oped slower in HT-29 cells (Fig. 4a). When pazopanib
was removed from the resistant cells (PAZ; cultured for
4 months in presence of the drug), sensitivity was deter-
mined after 1, 2 and 4 weeks of withdrawal. The recov-
ery was found to be rapid in both cell lines and to be
nearly complete within 1 week (Fig. 4b).
4 Discussion
Previously, we reported in vitro induction of resistance to su-
nitinib after prolonged, continuous exposure of 786-O and
HT-29 cancer cell lines to this tyrosine kinase inhibitor
(TKI) [8]. Induction of resistance was accompanied by an
increased intracellular accumulation of sunitinib and an in-
crease of the lysosomal compartment, as indicated by an in-
creased expression of the lysosome-associated membrane pro-
teins LAMP-1 and LAMP-2. The resistance phenotype was
found to be transient and reversible upon removal of sunitinib
(8–12 weeks). In the present study, we aimed to determine
whether sunitinib-resistant cancer cell lines may exhibit
cross-resistance to other targeted agents, and whether resis-
tance induction in this experimental context is a common fea-
ture of TKIs. We tested pazopanib, sorafenib and everolimus,
as TKIs that are used interchangeably or consecutively for the
treatment of renal cell cancer and two other TKIs with distinct
modes of action, i.e., lapatinib and erlotinib. As in our previ-
ous reports, we used the 786-O renal cell cancer (RCC) cell
line, representative of a tumor type in which sunitinib, soraf-
enib and pazopanib exhibit single agent activities, and the HT-
29 colorectal cancer (CRC) cell line which represents a tumor
type in which these three drugs exhibit activity at best in a
small subset of patients. This latter observation underscores
the need to understand in depth the effect of prolonged admin-
istration of these agents, also in CRC [16]. We found cross-
resistance of the sunitinib-resistant cell lines to the TKIs
pazopanib and erlotinib, but not to sorafenib, lapatinib or
everolimus. A similar resistance pattern was observed when
the parental cell lines were exposed for several months to
sorafenib, pazopanib or erlotinib, i.e., induction of resistance
to pazopanib or erlotinib was found, but not to sorafenib. The
development of (cross-) resistance was accompanied by an
increased intracellular accumulation of the respective drugs
and an elevated expression of the lysosomal membrane pro-
teins LAMP-1 and LAMP-2 in the resistant cells, suggesting
an involvement of the lysosomal compartment in the respec-
tive cellular adaptations. In addition, we found that resistance
to pazopanib could be rapidly induced (in 786-O cells) and
reversed within a few weeks after drug withdrawal.
Considering the potential mechanism(s) causing resistance
to TKIs in cancer, we selected tumor cell lines and clinically
approved agents to mimic the long-term use of these agents
and the resulting resistance patterns observed in patients. In a
clinical setting, these drugs are often applied continuously,
over prolonged periods of time, of which RCC constitutes a
prototype example. It is commonly assumed that mutations
arising under selective pressure during therapy account for
the development of acquired resistance. However, in contrast
to e.g., chronic myeloid leukemia (CML) and gastrointestinal
stromal tumors (GIST), where oncogene addiction is clearly at
work, no resistance mutations have been discovered in
Table 1 Cross-resistance of sunitinib-resistant cells
IC50 value (μM) Resistance factor
Drug Cell line PAR SUN
Sunitinib 786-O 1.4 4.2 3.1 ***
HT-29 0.90 3.7 4.1 ***
Sorafenib 786-O 2.7 3.4 1.2 *
HT-29 2.0 3.7 1.8 **
Pazopanib 786-O 6.5 10 1.6
HT-29 0.80 18 22 ***
Erlotinib 786-O 4.4 >20 >4.5 a
HT-29 6.3 >20 >3.2 a
Lapatinib 786-O 4.6 6.4 1.4
HT-29 2.1 4.2 2.0 ***
Everolimus 786-O 0.57×10−3 13×10−3 23
HT-29 10 23 2.4 *
IC50 values of 786-O and HT-29 parental (PAR) and sunitinib-resistant
(SUN) cell lines determined byMTT proliferation assays. IC50 values are
shown as means (n=2–3). Resistance factors are calculated by dividing
the IC50 values of the sunitinib-resistant cell lines by the IC50 value of the
parental cell line, and is denoted ‘cross-resistant’ when >2.5
*p value<0.05; **p value<0.01; ***p value<0.001; a , p value not avail-
able because IC50 was not reached
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primary RCCs or in RCC-derived cell lines that would con-
stitute indisputable proof that this mutated kinase is required
for tumor growth and/or survival [17]. Although sunitinib is
used clinically to treat c-KIT driven GISTs, efficient growth
inhibition of HT-29 CRC cells or xenografts requires a simul-
taneous block of EGFR [18, 19] or c-MET [20] kinases, in
addition to BRAFV600E, consistent with the very low response
rate (about 5 %) in BRAF-mutant CRCs. Although the
a
b
Fig. 2 Cross-resistance of sunitinib-resistant cells. (a) cross-resistance
patterns, determined by MTT proliferation assays, of the sunitinib-
resistant 786-O SUN and HT-29 SUN cell lines to sorafenib, pazopanib,
erlotinib, lapatinib or everolimus compared to parental (PAR) cell lines.
(b) intracellular accumulation of sorafenib, pazopanib or erlotinib in pa-
rental (PAR) and sunitinib-resistant (SUN) cells. Cells were incubated for
24 h with drug-containing medium at the~IC50 concentration of the pa-
rental cell line (except sunitinib itself). Drug concentrations: sunitinib:
5 μM (786-O) or 10 μM (HT-29); sorafenib: 2 μM (both cell lines);
pazopanib: 4 μM (786-O) or 2 μM (HT-29); erlotinib: 5 μM (both cell
lines). Results are shown as mean ± SEM (n=2–3). *, p value<0.05; **, p
value<0.01; ***, p value<0.001











Fig. 3 Induction of resistance to sorafenib, pazopanib and erlotinib. (a)
resistance patterns, determined byMTT proliferation assays, of the 786-O
and HT-29 cells continuously exposed to sorafenib (SOR), pazopanib
(PAZ) or erlotinib (ERL) for 3–4 months. (b) intracellular accumulation
of sorafenib, pazopanib or erlotinib in parental (PAR) and continuously
exposed SOR, PAZ and ERL cells. PAR cells were incubated for 24 h
with drug-containing medium at the concentration of the continuous ex-
posure. Drug concentrations: sorafenib: 3 μM; pazopanib: 20 μM;
erlotinib: 20 μM. (c) Western blot analysis of lysosome-associated mem-
brane protein-1 and −2 (LAMP-1 and −2), as a measure of the lysosomal
compartment. (d) quantification of LAMP-1 and −2 by Western blot
analysis. LAMP-1 and LAMP-2 expression was corrected for β-actin
expression, and normalized to untreated samples (PAR). P values are
derived from comparison to the PAR cell line. Results are shown as mean
± SEM. *, p value<0.05; **, p value<0.01; ***, p value<0.001
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delineation of resistance mechanisms to VEGF inhibitors is an
intense field of investigation, it appears plausible that adapta-
tion to treatment, including up-regulation of distinct angiogen-
ic mediators [21] and reversible epithelial to mesenchymal
transition (EMT) [22], may be relevant to this group of agents.
Our results do support this notion, since resistance was found
to be temporary and to be preserved only under continued
drug exposure. Upon removal, the cells rapidly recovered their
original sensitivity.
At the growth inhibitory IC50 of sunitinib (1–2 μM) several
major downstream substrates of (receptor) tyrosine kinases are
known to be inhibited, such as p-Akt(Ser473) and/or p-ERK1/
2(Thr202/Tyr204) and/or p-STAT3(Tyr705) [23]. Given the ap-
parent lack of one single targetable kinase sufficient to cause
effective growth inhibition in the cell lines tested, it is plausible
that a more general low level inhibition of several upstream
receptors and/or non-receptor kinases converges to the down-
stream effects of multi-targeted TKIs like sunitinib and sorafenib
[24]. A number of kinases, which have in comprehensive in vitro
kinase catalytic activity assays been found to be moderately
inhibited by sunitinib [25], are highly phosphorylated in HT-29
and 786-O cells, including Axl and RSK4 [20, 26]. Therefore,
combined inhibition of these, as well as a number of other abun-
dant kinases such asAMPK [27] or possibly high affinity kinases
expressed at a low level such as CSFR1 [28], could lead to
disruption of proper downstream survival signals. Similar to su-
nitinib, these considerations also apply to sorafenib and
pazopanib, which have a partially overlapping kinase inhibition
Table 2 Induction of resistance to sorafenib, pazopanib or erlotinib
IC50 value (μM) Resistance factor
Drug Cell line PAR SOR/PAZ/ERL
Sorafenib 786-O 2.7 3.2 1.2 *
HT-29 2.0 2.5 1.2 *
Pazopanib 786-O 6.5 >20 >3.1 a
HT-29 0.80 >20 >25 a
Erlotinib 786-O 4.4 >20 >4.5 a
HT-29 6.3 >20 >3.2 a
IC50 values of 786-O and HT-29 parental (PAR) and sorafenib (SOR),
pazopanib (PAZ) or erlotinib (ERL) selected cell lines determined by
MTT proliferation assays. IC50 values are shown as means. Resistance
factors are calculated by dividing the IC50 value of the inhibitor selected
cell line by the IC50 value of the parental cell line, and is denoted ‘resis-
tant’ when >2.5
*, p value<0.05; a , p value is not available because IC50 was not reached
a
b
Fig. 4 Induction and recovery of
pazopanib-resistance. (a)
induction: sensitivity to
pazopanib after 1, 2 or 4 weeks of
culturing the parental cells (PAR)
in the presence of the drug, com-
pared to the pazopanib-resistant
cell line (PAZ; cultured for 3–
4 months). (b) recovery: sensitiv-
ity to pazopanib 1, 2 or 4 weeks
after drug withdrawal from the
pazopanib-resistant cells (PAZ;
cultured for 3–4 months), com-
pared to the parental cells (PAR).
Results are shown as mean ±
SEM
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profile [25, 29]. Knowledge of adaptations in these or other
kinase activity profiles, and on the possibility of kinome
reprogramming contributing to loss of sensitivity to these TKIs,
requires further phospho-proteomic based studies. Such studies
may lead to insight in promising combination therapies to im-
prove response rates, for instance by direct modulation of the
Akt/mTOR signaling pathway [30].
We found that resistance induction in 786-O and HT-29 pa-
rental cells to pazopanib and erlotinib bears characteristics resem-
bling resistance induction to sunitinib, i.e., increased intracellular
drug accumulation and increased levels of LAMP-1 and LAMP-
2 in the resistant cell lines. Pazopanib and erlotinib belong to the
same class of hydrophobic, membrane-permeable weak bases as
sunitinib, properties that could facilitate the accumulation of their
protonated form in the acidic lysosomes, thereby resulting in
increased accumulation and an increase in the lysosomal com-
partment. A recent study confirmed the lysosomal accumulation
of sunitinib and revealed a disturbed intra-lysosomal pH, leading
to leakage of lysosomal proteases into the cytosol [31]. As such,
this mechanismmay be implicated in cell death induction by this
type of TKIs. An increased stabilization of lysosomes by in-
creased LAMP-1 and LAMP-2 expression may contribute to
the resistance observed. Taking a closer look, however, some
differences between sunitinib-resistance and pazopanib- or
erlotinib-resistance do appear. First, pazopanib- or erlotinib-
resistant cells do not show cross-resistance to any of the other
drugs tested (data not shown), while sunitinib-resistant cells are
cross-resistant to pazopanib and erlotinib. In addition, pazopanib-
resistant cells regain sensitivity much faster (~one week after
drug removal) than sunitinib-resistant cells. Differences in time-
to-induction of resistance may affect the outcome (4 months for
pazopanib- or erlotinib-resistance versus more than one year for
sunitinib-resistance). Drug characteristics and metabolism may,
however, offer alternative explanations, i.e., resistance may also
be influenced by the efficiency of drug efflux by drug trans-
porters, such as P-glycoprotein, and the mutation-inducing prop-
erties of drugs [32]. For instance, though sunitinib and doxo-
rubicin exhibit very similar physicochemical properties fa-
cilitating lysosomal accumulation, and doxorubicin inter-
calates into the DNA causing mutations, sunitinib as TKI
affects survival signaling pathways, leading to both simi-
lar, but also distinct, cellular adaptations and resistance
mechanisms [33]. Our observation that resistance to soraf-
enib did not develop in these cell lines under similar con-
ditions indicates that subtle changes in physicochemical
properties of a particular drug, in combination with a dif-
ferent kinase inhibition profile, may result in differential
resistance patterns. We found that the lysosomal compart-
ment, as measured by LAMP1/2 expression, was not or
only moderately induced by sorafenib in the present sched-
ule, and that no intracellular accumulation of sorafenib was
detected after continuous exposure. Both findings support
an alternative resistance mechanism for sorafenib
compared to the other TKIs. A recent study showed that
sorafenib resistance in hepatocellular carcinoma cells may
at least partly be related to p38α (MAPK14)-dependent
MEK-ERK activation, but other downstream proteins,
such as STAT3, also seem to be important [34, 35]. Since
sensitivities to both sorafenib and everolimus are retained
in sunitinib-resistant and pazopanib-resistant cells,
switching to these drugs is a reasonable strategy when pro-
gression occurs in patients treated with sunitinib or
pazopanib. The observation that sunitinib-resistant cells
do not show cross-resistance to sorafenib is consistent with
results from clinical trials that revealed a survival benefit
for sorafenib in a second-line setting in patients who
progressed upon sunitinib treatment [36]. The mTOR in-
hibitor everolimus may, based on the differences between
these two classes of drugs (multi-targeted TKI versus
mTOR inhibitor), be an even more interesting candidate
for sequential therapy. In the past, everolimus has been
shown to prolong progression-free survival after failure
of VEGF-targeted therapy [37]. Furthermore, everolimus
is currently assessed as alternate treatment with pazopanib
in a rotating schedule in patients with RCC [38].
In conclusion, we found that tumor cells can develop
(cross-) resistance to TKIs, such as sunitinib, pazopanib and
erlotinib, which is accompanied by an increased intracellular
accumulation. In resistant cells, an increased lysosomal com-
partment was found that may cause lysosomal drug sequestra-
tion and, thereby, an increased intracellular accumulation that
may prevent intracellular drug activity. The notion that
prolonged administration of these TKIs may cause tumor cell
adaptations and (cross-) resistance to some, but not all, agents
tested is of relevance, since these agents are frequently con-
sidered for combination or sequential therapy. In addition,
lysosomal protein expression could serve as a candidate bio-
marker for these forms of drug resistance.
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